{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:18:32Z","timestamp":1791317912577,"version":"4.3.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":468,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Fondazione Credito Bergamasco"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>The identification of subjects at higher risk for incident heart failure (HF) with preserved ejection fraction (EF) suitable for more intensive preventive programmes remains challenging. We applied phenomapping to the DAVID-Berg population, comprising subjects with preclinical HF, aiming to refine HF risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The DAVID-Berg study prospectively enrolled 596 asymptomatic outpatients with EF &amp;gt; 40% with hypertension, diabetes mellitus or known cardiovascular disease. In this cohort, we performed an unsupervised cluster analysis on 591 patients, including clinical, laboratory, electrocardiographic and echocardiographic parameters. We tested the association between each cluster and a composite outcome of HF\/death.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median age was 70 years, 55.5% were males and the median EF was 61.0%. Phenomapping provided three different clusters. Subjects in Cluster 3 were the oldest and had the highest prevalence of atrial fibrillation, the lowest estimated glomerular filtration rate (eGFR), the highest N-terminal pro-brain natriuretic peptide (NT-proBNP) and the largest left atrium. During a median follow-up of 5.7 years, 13.4% of subjects experienced HF\/death events (N = 79). Compared with Clusters 1 and 2, Cluster 3 had the worst prognosis (log-rank test: Cluster 3 vs. 1 P &amp;lt; 0.001; Cluster 3 vs. 2 P = 0.008). Cluster 3 was associated with a risk of HF\/death 2.5 times higher than Cluster 1 [adjusted hazard ratio (HR) = 2.46, 95% confidence interval (CI) 1.24\u20134.90].<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Based on phenomapping, older patients with lower kidney function and worse diastolic function might represent a subset of preclinical HF with EF &amp;gt; 40% who deserve more efforts to prevent clinical HF.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14913","type":"journal-article","created":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T00:39:01Z","timestamp":1720139941000},"page":"3350-3359","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Long-Term Outcomes of Phenoclusters in Preclinical Heart Failure with Preserved and Mildly Reduced Ejection Fraction"],"prefix":"10.1093","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-7435","authenticated-orcid":false,"given":"Luca","family":"Fazzini","sequence":"first","affiliation":[{"name":"Clinical Cardiology Unit, Department of Medical Sciences and Public Health, University of Cagliari , Cagliari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arianna","family":"Ghirardi","sequence":"additional","affiliation":[{"name":"FROM Research Foundation, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Limonta","sequence":"additional","affiliation":[{"name":"School of Medicine and Surgery, University of Milan-Bicocca , Milan ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Calabrese","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilia","family":"D'Elia","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Canova","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fontana","sequence":"additional","affiliation":[{"name":"Cardiology Unit, ISMETT-IRCCS , Palermo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aurelia","family":"Grosu","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attilio","family":"Iacovoni","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renata","family":"De Maria","sequence":"additional","affiliation":[{"name":"National Research Council Clinical Physiology Institute , Pisa ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonello","family":"Gavazzi","sequence":"additional","affiliation":[{"name":"FROM Research Foundation, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Montisci","sequence":"additional","affiliation":[{"name":"Clinical Cardiology Unit, Department of Medical Sciences and Public Health, University of Cagliari , Cagliari ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Senni","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Gori","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Cardiovascular Department, Papa Giovanni XXIII Hospital , Bergamo ,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"2026012113145942300_ehf214913-bib-0001","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","article-title":"2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America","volume":"136","author":"Yancy","year":"2017","journal-title":"Circulation"},{"key":"2026012113145942300_ehf214913-bib-0002","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1161\/CIRCULATIONAHA.118.034646","article-title":"A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction","volume":"138","author":"Reddy","year":"2018","journal-title":"Circulation"},{"key":"2026012113145942300_ehf214913-bib-0003","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1093\/eurheartj\/ehz641","article-title":"How to diagnose heart failure with preserved ejection fraction: The HFA-PEFF diagnostic algorithm: A consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)","volume":"40","author":"Pieske","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012113145942300_ehf214913-bib-0004","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1161\/CIRCULATIONAHA.106.666818","article-title":"Prevalence and prognostic significance of heart failure stages: Application of the American College of Cardiology\/American Heart Association heart failure staging criteria in the community","volume":"115","author":"Ammar","year":"2007","journal-title":"Circulation"},{"key":"2026012113145942300_ehf214913-bib-0005","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/eurheartj\/ehi559","article-title":"What is the most cost-effective strategy to screen for left ventricular systolic dysfunction: Natriuretic peptides, the electrocardiogram, hand-held echocardiography, traditional echocardiography, or their combination?","volume":"27","author":"Galasko","year":"2006","journal-title":"Eur Heart J"},{"key":"2026012113145942300_ehf214913-bib-0006","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1177\/2047487319899618","article-title":"Integrating natriuretic peptides and diastolic dysfunction to predict adverse events in high-risk asymptomatic subjects","volume":"28","author":"Gori","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"2026012113145942300_ehf214913-bib-0007","doi-asserted-by":"publisher","first-page":"5093","DOI":"10.1016\/j.ijcard.2013.07.260","article-title":"Natriuretic peptides and the Framingham risk score for screening of asymptomatic left ventricular systolic dysfunction in high-risk patients in primary care. The DAVID-BERG study","volume":"168","author":"Iacovoni","year":"2013","journal-title":"Int J Cardiol"},{"key":"2026012113145942300_ehf214913-bib-0008","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ijcard.2017.06.101","article-title":"Strategy to identify subjects with diabetes mellitus more suitable for selective echocardiographic screening: The DAVID-Berg study","volume":"1","author":"Gori","year":"2017","journal-title":"Int J Cardiol"},{"key":"2026012113145942300_ehf214913-bib-0009","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1298","article-title":"Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study","author":"Gori","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"2026012113145942300_ehf214913-bib-0010","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2047487319896431","article-title":"Prolonged QRS associated with left bundle branch conduction defect is a prognostic red flag in asymptomatic heart failure (ACCF\/AHA stages A and B) patients: Insights from the DAVID-Berg study","volume":"0","author":"Pozzi","year":"2019","journal-title":"Eur J Prev Cardiol"},{"key":"2026012113145942300_ehf214913-bib-0011","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.007216","article-title":"Progression of preclinical heart failure: A description of stage A and B heart failure in a community population","volume":"14","author":"Young","year":"2021","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"2026012113145942300_ehf214913-bib-0012","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1177\/2047487314525529","article-title":"Metabolic syndrome across Europe: Different clusters of risk factors","volume":"22","author":"Scuteri","year":"2015","journal-title":"Eur J Prev Cardiol"},{"key":"2026012113145942300_ehf214913-bib-0013","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1016\/j.jacc.2010.01.031","article-title":"The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A\/B heart failure subjects","volume":"55","author":"McKie","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2026012113145942300_ehf214913-bib-0014","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/ehjci\/jev014","article-title":"Recommendations for cardiac chamber quantification by echocardiography in adults: An update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging","volume":"16","author":"Lang","year":"2015","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"2026012113145942300_ehf214913-bib-0015","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1016\/j.jacc.2006.02.048","article-title":"Left atrial size: Physiologic determinants and clinical applications","volume":"47","author":"Abhayaratna","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"2026012113145942300_ehf214913-bib-0016","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ejhf.1436","article-title":"The role of ventricular-arterial coupling in cardiac disease and heart failure: Assessment, clinical implications and therapeutic interventions. A consensus document of the European Society of Cardiology Working Group on Aorta & Peripheral Vascular Diseases, European Association of Cardiovascular Imaging, and Heart Failure Association","volume":"21","author":"Ikonomidis","year":"2019","journal-title":"Eur J Heart Fail"},{"key":"2026012113145942300_ehf214913-bib-0017","doi-asserted-by":"publisher","first-page":"2254","DOI":"10.1161\/CIRCULATIONAHA.115.020729","article-title":"Importance of clinical worsening of heart failure treated in the outpatient setting: Evidence from the prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF)","volume":"133","author":"Okumura","year":"2016","journal-title":"Circulation"},{"key":"2026012113145942300_ehf214913-bib-0018","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"2026012113145942300_ehf214913-bib-0019","doi-asserted-by":"publisher","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: A comprehensive and updated review of epidemiology","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026012113145942300_ehf214913-bib-0020","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113145942300_ehf214913-bib-0021","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"2026012113145942300_ehf214913-bib-0022","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1093\/eurheartj\/ehs205","article-title":"The role of the kidney in heart failure","volume":"33","author":"Metra","year":"2012","journal-title":"Eur Heart J"},{"key":"2026012113145942300_ehf214913-bib-0023","doi-asserted-by":"publisher","first-page":"3403","DOI":"10.1093\/cvr\/cvac179","article-title":"Phenomapping in heart failure with preserved ejection fraction: Insights, limitations, and future directions","volume":"118","author":"Peters","year":"2023","journal-title":"Cardiovasc Res"},{"key":"2026012113145942300_ehf214913-bib-0024","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1161\/CIRCULATIONAHA.120.050686","article-title":"Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options","volume":"143","author":"Jankowski","year":"2021","journal-title":"Circulation"},{"key":"2026012113145942300_ehf214913-bib-0025","doi-asserted-by":"publisher","first-page":"3442","DOI":"10.1093\/eurheartj\/ehu254","article-title":"Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction","volume":"35","author":"Gori","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012113145942300_ehf214913-bib-0026","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/ehf2.13695","article-title":"Risk factors for asymptomatic echocardiographic abnormalities that predict symptomatic heart failure","volume":"9","author":"Coller","year":"2022","journal-title":"ESC Heart Fail"},{"key":"2026012113145942300_ehf214913-bib-0027","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026030","article-title":"Plasma NT-proBNP levels associated with cardiac structural abnormalities in asymptomatic health examinees with preserved ejection fraction: A retrospective cross-sectional study","volume":"9","author":"Nah","year":"2019","journal-title":"BMJ Open"},{"key":"2026012113145942300_ehf214913-bib-0028","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3024","article-title":"2023 focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"2026012113145942300_ehf214913-bib-0029","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113145942300_ehf214913-bib-0030","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","journal-title":"N Engl J Med"},{"key":"2026012113145942300_ehf214913-bib-0031","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113145942300_ehf214913-bib-0032","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2026012113145942300_ehf214913-bib-0033","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2026012113145942300_ehf214913-bib-0034","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: Analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"key":"2026012113145942300_ehf214913-bib-0035","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC)","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"2026012113145942300_ehf214913-bib-0036","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1161\/CIRCHEARTFAILURE.114.001276","article-title":"Left atrium in heart failure with preserved ejection fraction: Structure, function, and significance","volume":"7","author":"Rossi","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2026012113145942300_ehf214913-bib-0037","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/heartjnl-2022-321097","article-title":"Management of patients with heart failure and preserved ejection fraction","volume":"109","author":"Jasinska-Piadlo","year":"2023","journal-title":"Heart"},{"key":"2026012113145942300_ehf214913-bib-0038","volume-title":"Chronic heart failure in adults: Diagnosis and management","author":"National Institute for Health and Care Excellence","year":"2018"},{"key":"2026012113145942300_ehf214913-bib-0039","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: Current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur Heart J"},{"key":"2026012113145942300_ehf214913-bib-0040","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1002\/ejhf.2848","article-title":"Natriuretic peptides: Role in the diagnosis and management of heart failure: A scientific statement from the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society","volume":"25","author":"Tsutsui","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113145942300_ehf214913-bib-0041","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1001\/jama.289.2.194","article-title":"Burden of systolic and diastolic ventricular dysfunction in the community: Appreciating the scope of the heart failure epidemic","volume":"289","author":"Redfield","year":"2003","journal-title":"JAMA"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/3350\/64514775\/eschf_11_5_3350.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/5\/3350\/64514775\/eschf_11_5_3350.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:16:56Z","timestamp":1769019416000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/5\/3350\/8271270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":41,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,7,4]]},"published-print":{"date-parts":[[2024,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14913","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,10]]},"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"2024-03-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}